Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.58 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TYR | P14679 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045964 | 0.96 | ALDH1A1 (0.58) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| SCHEMBL25946999 | 0.76 | MAOA (0.49) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| SCHEMBL38604 | 0.75 | ALOX15 (1.00) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| SCHEMBL1535914 | 0.75 | MAPT (0.59) | ALDH1A1ALOX15KDM4EMAPTHSD17B10 | |
| SCHEMBL21415519 | 0.74 | HPGD (0.31) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| SCHEMBL31310910 | 0.73 | ALOX15 (0.94) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| Methane SCHEMBL28686923 | 0.73 | ALOX15 (0.94) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| SCHEMBL67854 | 0.73 | ALOX15 (0.82) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| SCHEMBL16239320 | 0.72 | MEN1 (0.46) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT | |
| SCHEMBL10388767 | 0.72 | ALDH1A1 (0.50) | ALDH1A1ALOX15SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997050-B1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA SRL (IT) | 2018-01-17 | — | — | EP | disclosed |
| US-9714303-B2 | Catalyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2017-07-25 | — | — | US | disclosed |
| US-20160115261-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia, s.r.l. (IT) | 2016-04-28 | — | — | US | disclosed |
| EP-2997050-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia S.r.l. (IT) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184171-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2014-11-20 | — | — | WO | disclosed |
| EP-2803678-A1 | Catalyst components for the polymerization of olefins | Basell Poliolefine Italia S.r.l. (IT) | 2014-11-19 | — | — | EP | disclosed |
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDICK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| EP-1881961-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120178-A1 | NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041657-A1 | HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES | RPS12, GPR119, ATP12A | ALDH1A1 899/4885ALOX15 467/4885SMN1; SMN2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.